Telerobotic surgery is shifting from isolated demonstrations toward broader clinical and regulatory development, and SS Innovations International (NASDAQ: SSII) is positioning itself at the center of that transition. A recent MedTech Dive article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s progress and the questions surrounding remote surgery. The report highlighted SS Innovations International (NASDAQ: SSII) alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
For SS Innovations, the discussion comes as its SSi Mantra system accumulates real-world experience in telesurgery. The company reported 195 robotic telesurgeries using the system as of Sept. 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 SSi Mantra systems as of that date, up 45% from the end of 2025, while cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
CEO Dr. Sudhir Srivastava, a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. That framing matters because telesurgery could extend specialized surgical expertise to underserved regions, but it also raises regulatory and infrastructure hurdles. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand into additional international markets. Those approvals could determine whether the company can compete in the world’s largest healthcare markets.
The growing interest in remote procedures puts SS Innovations in an increasingly relevant part of the surgical robotics market. The MedTech Dive report underscored that while the technology is advancing globally, U.S. adoption remains an open question. For investors, the company’s procedure volumes and installed base growth offer tangible metrics of traction. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
MissionIR, a specialized communications platform, distributes content to enhance visibility for private and public companies through a Dynamic Brand Portfolio within IBN. Its offerings include wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. These channels help companies like SS Innovations reach a wide audience of investors and journalists.
The implications of SS Innovations’ progress extend beyond its own balance sheet. If telesurgery gains regulatory acceptance, it could reshape how surgical care is delivered, particularly in areas with limited access to specialists. However, questions about latency, liability, and cross-border regulation remain. The company’s pursuit of FDA and CE marks will be critical tests. As remote procedures gain ground, SS Innovations’ early experience and expanding footprint may give it a first-mover advantage—or expose it to heightened scrutiny. Either way, its trajectory will be watched closely as a bellwether for the telerobotic surgery market.
